&lt;p&gt;UPF1 Participates in the Progression of Endometrial Cancer by Inhibiting the Expression of lncRNA PVT1&lt;/p&gt;

Xing, Tian-Rong; Chen, Ping; Wu, Jia-Mei; Gao, Lili; Yang, Wei; Cheng, Yu; Li-bo, Tong

doi:10.2147/ott.s233149

Cited by 15 publications

(6 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, UPF1 is considered to mediate the degradation of the substrates of NMD via a phosphorylation/dephosphorylation cycle [ 38 , 39 ]. In tumorigenesis, recent investigations have demonstrated the inhibitory role of UPF1 in tumor progression in multiple cancers [ 40 – 42 ]. In HCC, UPF1 was demonstrated to act as a tumor suppressor via multiple pathways.…”

Section: Discussionmentioning

confidence: 99%

RBM47 inhibits hepatocellular carcinoma progression by targeting UPF1 as a DNA/RNA regulator

et al. 2022

View full text Add to dashboard Cite

The mechanisms by which the tumor behaviors of hepatocellular carcinoma (HCC) support growth and metastasis remain largely unknown, and it has become increasingly apparent that molecular dysregulation is of considerable importance for cellular signaling pathways. Recently, RNA-binding motif protein 47 (RBM47) has been suggested to function as a tumor regulator by acting as an RNA binding protein (RBP), but its role in HCC remains ambiguous. Here, in HCC, we identified that RBM47 had an inhibitory influence on tumor behaviors in vitro and accordingly suppressed the growth and metastasis of xenograft tumors in vivo. Additionally, RBM47 was verified to positively regulate Upframeshift 1 (UPF1), which is a crucial protein involved in the nonsense-mediated RNA decay (NMD) process and was previously determined to be an HCC suppressor. Mechanistically, the stability of UPF1 mRNA was demonstrated to be enhanced with its 3’UTR bound by RBM47, which acted as an RNA binding protein. Meanwhile, RBM47 was also proven to promote the transcription of UPF1 as a transcription factor. Taken together, we concluded that RBM47 functioned as a tumor suppressor by upregulating UPF1, acting as a DNA/RNA binding protein at the transcriptional and posttranscriptional levels.

show abstract

Section: Discussionmentioning

confidence: 99%

RBM47 inhibits hepatocellular carcinoma progression by targeting UPF1 as a DNA/RNA regulator

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Up‐frameshift protein 1 (UPF1) expressions were downregulated in EC tissues and cells and negatively correlated with lncRNA PVT1 expression levels. Furthermore, the downregulation of PVT1 was discovered to inhibit EC cell glycolysis 27 . Zhang et al 28 reported that an excess amount of SNHG16 lifted HK2 expression levels by sponging miR‐490‐3p, which subsequently promoted cell proliferation and glycolysis.…”

Section: Discussionmentioning

confidence: 99%

Knockdown of long non‐coding RNA small nucleolar RNA host gene 9 or hexokinase 2 both suppress endometrial cancer cell proliferation and glycolysis

Wang

Huang

Lin

et al. 2021

J of Obstet and Gynaecol

View full text Add to dashboard Cite

Aim Endometrial cancer (EC) is a common type of malignant gynecological cancer. Small nucleolar RNA host gene 9 (SNHG9) has been discovered to serve a role in several types of cancer; however, the role of SNHG9 in EC remains unclear. The present study aimed to investigate the effects of lncRNA SNHG9 on cell proliferation and glycolysis in EC cells. Methods SNHG9 and hexokinase 2 (HK2) mRNA expression levels were measured by reverse transcription‐quantitative PCR. Glucose consumption and lactate production were detected by the glycolysis cell‐based assay kit. Cell Counting Kit‐8 and colony formation assays were conducted to detect cell proliferation. The knockdown experiments of SNHG9 and HK2 were carried out by transfection of corresponding small interference RNAs (siRNA). The SNHG9‐overexpressed plasmid was transfected into the cells to upregulate SNHG9. HK2 protein levels were analyzed by western blotting assay. Results SNHG9 expression levels were significantly upregulated in EC tissues and cells. The knockdown of SNHG9 subsequently effectively attenuated cell proliferation and glycolysis in vitro, while SNHG9 overexpression reported the opposite effects. Notably, the transfection of 2‐DG partially reversed the promoting effect of SNHG9 on glycolysis. Downregulation of HK2 markedly decreased cell proliferation and glycolysis in EC cells antagonized SNHG9. Conclusion Either downregulation of SNHG9 or HK2 inhibits EC cell proliferation and glycolysis via repressing EC cell proliferation and glycolysis.

show abstract

“…(D,E) Survival curves of NOL3 and UPF3B. *p < 0.05, **p < 0.01. endometrial carcinoma (Xing et al, 2020). UPF3A partially contributes to the effect of calcium homeostasis endoplasmic reticulum protein (CHERP) in promoting tumorigenesis in CRC (Wang Q. et al, 2019).…”

Section: Discussionmentioning

confidence: 99%

Molecular Characterization and Clinical Relevance of RNA Binding Proteins in Colorectal Cancer

et al. 2020

View full text Add to dashboard Cite

Abnormal expression of RNA binding proteins (RBPs) has been reported across various cancers. However, the potential role of RBPs in colorectal cancer (CRC) remains unclear. In this study, we performed a systematic bioinformatics analysis of RBPs in CRC. We downloaded CRC data from The Cancer Genome Atlas (TCGA) database. Our analysis identified 242 differentially expressed RBPs between tumor and normal tissues, including 200 upregulated and 42 downregulated RBPs. Next, we found eight RBPs (RRS1, PABPC1L, TERT, SMAD6, UPF3B, RP9, NOL3, and PTRH1) related to the prognoses of CRC patients. Among these eight prognosis-related RBPs, four RBPs (NOL3, PTRH1, UPF3B, and SMAD6) were selected to construct a prognostic risk score model. Furthermore, our results indicated that the prognostic risk score model accurately predicted the prognosis of CRC patients [area under the receiver operating characteristic curve (AUC)for 3-and 5-year overall survival (OS) and was 0.645 and 0.672, respectively]. Furthermore, we developed a nomogram based on a prognostic risk score model. The nomogram was able to demonstrate the wonderful performance in predicting 3-and 5-year OS. Additionally, we validated the clinical value of four risk genes in the prognostic risk score model and identified that these risk genes were associated with tumorigenesis, lymph node metastasis, distant metastasis, clinical stage, and prognosis. Finally, we used the TIMER and Human Protein Atlas (HPA)database to validate the expression of four risk genes at the transcriptional and translational levels, respectively, and used a clinical cohort to validate the roles of NOL3 and UPF3B in predicting the prognosis of CRC patients. In summary, our study demonstrated that RBPs have an effect on CRC tumor progression and might be potential prognostic biomarkers for CRC patients.

show abstract

<p>UPF1 Participates in the Progression of Endometrial Cancer by Inhibiting the Expression of lncRNA PVT1</p>

Cited by 15 publications

References 29 publications

RBM47 inhibits hepatocellular carcinoma progression by targeting UPF1 as a DNA/RNA regulator

RBM47 inhibits hepatocellular carcinoma progression by targeting UPF1 as a DNA/RNA regulator

Knockdown of long non‐coding RNA small nucleolar RNA host gene 9 or hexokinase 2 both suppress endometrial cancer cell proliferation and glycolysis

Molecular Characterization and Clinical Relevance of RNA Binding Proteins in Colorectal Cancer

Contact Info

Product

Resources

About